This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
Amarin (NASDAQ:AMRN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights [Yahoo! Finance]
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization